Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours.
Pape
Ulrich Frank
UF
Division of Hepatology and Gastroenterology & Interdisciplinary, Centre of Endocrinology and Metabolism, Department of Internal Medicine, Charité, Campus Virchow Klinikum, Berlin, Germany.
Wiedenmann
Bertram
B